PGH-Secreting Probiotic Strains for Diarrhea Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotic strains used to treat diarrhea and Clostridium difficile infections do not produce bacteriocins or antimicrobial enzymes, limiting their effectiveness against pathogenic bacteria, and existing treatments have drawbacks such as rapid degradation and side effects on beneficial gut bacteria.
Innovation Solution
Development of bacterial peptidoglycan hydrolase (PGH)-secreting probiotic strains, such as Lactococcus lactis and Lactobacillus species, which produce N-acetylglucosaminidase and other glycosidases to disrupt pathogenic bacteria's peptidoglycan layer, providing antimicrobial activity against Clostridium difficile and other pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotic strains (L. rhamnosus LGG, S. boulardii) are used to treat diarrhea, then some therapeutic benefit is achieved, but the effectiveness is limited and modest (reduction of diarrhea duration of approximately one day)
Solution Approach 1:
The patent modifies the probiotic strain by introducing foreign genes (lytA, lytB, lytC, mprF) that encode peptidoglycan hydrolase enzymes. This genetic parameter change enables the probiotic to produce antimicrobial substances it would not normally produce, thereby significantly enhancing its therapeutic effectiveness against C. difficile while maintaining its probiotic status.
Solution Approach 2:
The patent creates a composite probiotic system by combining the native properties of beneficial probiotic bacteria with exogenously introduced peptidoglycan hydrolase enzymes. This composite approach allows the probiotic to simultaneously maintain gut flora balance and actively degrade pathogenic bacterial cell walls, achieving synergistic therapeutic effects that exceed the sum of individual components.
2Reliability
If antibiotics are used to treat C. difficile infections, then pathogenic bacteria are eliminated, but side effects occur including harm to beneficial gut bacteria and rapid degradation of the treatment
Solution Approach 1:
The patent confers antimicrobial capability specifically to the probiotic strain through genetic modification, creating a localized antimicrobial effect targeted at C. difficile. The peptidoglycan hydrolase enzymes are produced by and act locally at the site of probiotic colonization in the gut, selectively degrading pathogenic bacteria while sparing beneficial flora that lack the vulnerable peptidoglycan structures.
Solution Approach 2:
The patent exploits the structural vulnerability of C. difficile's peptidoglycan layer by introducing peptidoglycan hydrolase enzymes. The very cell wall structure that protects bacteria is converted into a target for degradation by the modified probiotic, turning the pathogen's defensive feature into its Achilles' heel while leaving beneficial bacteria unaffected.
3Adaptability or versatility
If probiotic strains are administered to restore intestinal microflora, then gut flora balance is improved, but the strains lack bacteriocin or antimicrobial enzyme production capability
Solution Approach 1:
The patent transforms the probiotic strain into a multi-functional organism that simultaneously performs classic probiotic functions (restoring gut flora balance, producing lactic acid, maintaining intestinal health) and acquires new antimicrobial functions through peptidoglycan hydrolase production. This universal probiotic can address both microbiota restoration and pathogen elimination.
Solution Approach 2:
The patent prepares the probiotic strain in advance by introducing peptidoglycan hydrolase genes before administration. This preliminary genetic modification ensures that the probiotic is pre-equipped with antimicrobial capability upon reaching the gut, eliminating the need for separate antimicrobial treatments and enabling immediate action against C. difficile upon colonization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PGH-secreting probiotic strains effectively inhibit Clostridium difficile and other pathogens, maintaining activity across a pH range relevant to the intestine without harming beneficial gut bacteria, offering a more effective treatment for diarrhea and Clostridium difficile infections.
Implementation Method 1
bacterial peptidoglycan hydrolase (PGH)-secreting probiotic strains, such as Lactococcus lactis and Lactobacillus species, which produce N-acetylglucosaminidase and other glycosidases to disrupt pathogenic bacteria's peptidoglycan layer
Data Source
AI summary
The present invention is directed to a bacterial, preferably probiotic bacterial peptidoglycan hydrolase (PGH), a peptidoglycan hydrolase (PGH)-comprising bacterial, preferably probiotic bacterial strain or a peptidoglycan hydrolase (PGH)-comprising composition for use in the therapeutic or prophylactic treatment of a bacterial infection, preferably for the treatment of a bacterial infection resulting in diarrhea. Further aspects of the present invention relate to corresponding methods for preparing a medicament and to a corresponding method of treatment.